Biocryst Pharmaceuticals Inc

  • Health Care
  • Biotechnology: Biological Products (No Diagnostic Substances)
  • www.biocryst.com
  • Safety Score
  • Market Cap $2.12B
  • Debt $314.87M
  • Cash $104.71M
  • EV $2.33B
  • FCF -$53.14M

Earnings

loading chart...

Sales & Net Margins

loading chart...
Earnings-$88.88M
EBIT-$2.54M
ROA-1%
FCF-$53.14M
Equity-$475.93M
Growth Stability1
PE-23.89
PB-4.46
P/FCF-39.96
P/S4.71
Price/Cash0.05
Debt/Equity-0.66
Debt/FCF-5.92
Net Margins-20%
Gross Margins97%
Op. Margins-1%
Sales Growth YoY41%
Sales Growth QoQ12%
Sales CAGR52%
Equity CAGR0%
Earnings Growth YoY-57%
Earnings Growth QoQ91%
Sales CAGR 5Y81%
Earnings CAGR 3Y34%
Sales CAGR 3Y34%
Market Cap$2.12B
Revenue$450.71M
Assets$490.42M
Total Debt$314.87M
Cash$104.71M
Shares Outstanding206.7M
EV2.33B
Safety Score37%
Working Capital261.58M
Current Ratio2.63
Gross Profit$438.44M
Shares Growth 3y5%
Equity Growth QoQ2%
Equity Growth YoY4%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, with the aim of blocking key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.

SEC Filings

Direct access to Biocryst Pharmaceuticals Inc (BCRX) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

  • 2024
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2023
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2022
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31

Sector Comparison

How does Biocryst Pharmaceuticals Inc compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Biocryst Pharmaceuticals Inc compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Biocryst Pharmaceuticals Inc Discounted Cash Flow

Fully customizable DCF calculator online for Biocryst Pharmaceuticals Inc.

= -$531M
012345678910TV
fcf-$53M-$53M-$53M-$53M-$53M-$53M-$53M-$53M-$53M-$53M-$53M-$531M
DCF-$48M-$44M-$40M-$36M-$33M-$30M-$27M-$25M-$23M-$20M-$205M
Value-$531M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years12/201512/201612/201712/201812/201912/202012/202112/202212/202312/2024TTM
Net Margins-89%-209%-261%-490%-223%-1K%-117%-91%-68%-20%-20%
ROA--54%-32%-64%-57%-50%-30%-27%-20%-1%-1%
ROE--3K%-79%-206%-285%949%172%84%50%19%-

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years12/201512/201612/201712/201812/201912/202012/202112/202212/202312/2024TTM
Debt over FCF--0.87-1.25-0.64-0.88-1.11-2.06-1.42-3.12-5.92-5.92
Debt over Equity0.6332.470.621.22.08-7.92-2.79-0.79-0.67-0.66-0.66
Growth Stability----------1

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years12/201512/201612/201712/201812/201912/202012/202112/202212/202312/2024CAGR 5Y
Revenue YoY growth--45%-4%-18%136%-64%782%72%22%36%81%
Earnings YoY growth-28%19%54%8%68%1%34%-8%-61%-
Equity YoY growth--97%5K%-41%-22%-150%455%175%55%4%-
FCF YoY growth-222%-29%124%-3%53%5%13%-40%-45%-